Three studies at ADA 2018 highlight the current track record of SGLT-2is in reducing CV-related morbidity and mortality.
Once-Monthly Maridebart Cafraglutide Produces Up to 20% Weight Loss in Phase 2 Trial
ADA 2025: Once-monthly dosing led to significant weight loss in adults with obesity, with or without type 2 diabetes, reported researchers.
Obesity & Type 2 Diabetes: An Expert Discussion
In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
Orforglipron, an Investigational Oral GLP-1, Cuts HbA1c and Body Weight in People With T2D
ADA 2025: Orforglipron lowered HbA1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as 4 weeks, in a phase 3 trial.
Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.
ADA Standards of Care for Overweight and Obesity to Debut at 2025 Scientific Sessions
The ADA unveils the association's first Standards of Care for Overweight and Obesity, with a chapter on weight stigma and bias one of the first released.
Coexisting HTN, T2D in US Adults Doubled Over 2 Decades: Daily Dose
Your daily dose of the clinical news you may have missed.